A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Nov 16, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the JUNS SEC filings page.
Jupiter Neurosciences, Inc. (JUNS) reported $22K in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Jupiter Neurosciences remains development-stage, with $22K of revenue against multi-million-dollar R&D and SG&A spending.
The 2025 operating loss of$8.9M against just$22K of revenue shows that the company’s current cost base is far ahead of commercial activity. R&D and SG&A were both measured in millions, so the reported80.6% gross margin did not translate into operating profitability; spending scale is more informative than gross margin at this stage.
Balance-sheet flexibility deteriorated sharply. Equity moved from
Operations were not self-funding. Operating cash outflow rose from
Financial Health Signals
We do not publish a peer-relative financial health score for Jupiter Neurosciences, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Jupiter Neurosciences, Inc. scores -14.42, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $34.7M against total assets of $5.6M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Jupiter Neurosciences, Inc. passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), the one computable operating efficiency signal (asset turnover improving) passes.
Jupiter Neurosciences, Inc. reported a net loss of $8.6M while operations used $5.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Jupiter Neurosciences, Inc. reported an operating loss of $8.9M against $66K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Jupiter Neurosciences, Inc. generated $14K in revenue in Q3 2026. Against the prior quarter it is down 42.5%.
Jupiter Neurosciences, Inc. reported a net loss of $7.2M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q3 2026.
Cash & Balance Sheet
Jupiter Neurosciences, Inc. held $301K in cash as of Q3 2026; no long-term debt figure is on record for that period.
Not reported for Q3 2026.
Not reported for Q3 2026.
Margins & Returns
Jupiter Neurosciences, Inc.'s gross margin was 68.9% in Q3 2026, indicating the percentage of revenue retained after direct costs. Against the prior quarter it is down 18.0 percentage points.
Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not reported for Q3 2026.
Capital Allocation
Jupiter Neurosciences, Inc. invested $3.9M in research and development in Q3 2026. This represents an increase of 376.6% from the same quarter a year earlier. Against the prior quarter it is up 548.3%.
Not reported for Q3 2026.
Not reported for Q3 2026.
JUNS Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14K | $24K | $19Kn/m | N/A | N/A | N/A | $0 | N/A |
| Cost of Revenue | $4K | $3K | $4K | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $10K | $21K | $14K | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $3.9M+376.6% | $600K-20.9% | $411K-11.9% | $44K-78.3% | $817K+788.6% | $759K+651.4% | $467K+373.1% | $201K |
| SG&A Expenses | $1.9M+29.2% | $2.2M+43.7% | $1.6M+46.2% | $2.8M | $1.5M+268.6% | $1.5M+230.1% | $1.1M+126.9% | N/A |
| Operating Income | -$5.8Mn/m | -$2.7Mn/m | -$2.0Mn/m | -$2.8M | -$2.3Mn/m | -$2.3Mn/m | -$1.5Mn/m | N/A |
| Interest Expense | $68K+5608.1% | $91K+7884.0% | $119K+9553.7% | $62K | $1K-98.9% | $1K-98.0% | $1K-98.1% | N/A |
| Net Income | -$7.2Mn/m | -$2.3Mn/m | -$2.1Mn/m | -$2.6Mn/m | -$2.3Mn/m | -$2.3M-819.5% | -$1.5Mn/m | -$1.5Mn/m |
| EPS (Basic) | -$7.42 | -$4.08n/m | -$4.50n/m | -$5.25n/m | -$5.04n/m | -$5.09-778.7% | -$3.75n/m | -$3.75n/m |
| EPS (Diluted) | -$7.42 | -$4.08n/m | -$4.50n/m | -$5.25n/m | -$5.04n/m | -$5.09-778.7% | -$3.75n/m | -$3.75n/m |
| Diluted Shares (Avg) | 973,633 | 557,567+26.0% | 470,075+6.5% | N/A | 453,865+9.6% | 442,413+8.5% | 441,385+24.8% | N/A |
Not reported in any period shown, so not listed: EBITDA, Income Tax.
JUNS Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'25Filing | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.6M-37.0% | $3.7M-6.3% | $3.9M-20.4% | $5.6M-10.3% | $2.6M+2911.5% | $4.0M | $5.0M | $6.2M+4074.1% |
| Current Assets | $1.3M-22.9% | $2.5M-9.6% | $3.4M-5.6% | $4.8M+3.8% | $1.6M+317479.4% | $2.8M | $3.6M | $4.7M+16081.0% |
| Cash & Equivalents | $301K-58.5% | $1.5M-19.0% | $2.4M-12.7% | $3.8M+0.5% | $724K+285985.8% | $1.9M | $2.7M | $3.8M+13136.6% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0 | $0 | $0n/m |
| Inventory | $131K | $135K | $148K | $160K | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | $10K | N/A | $3K | N/A | N/A | N/A | N/A |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0 | $0 | $0n/m |
| Total Liabilities | $2.8M+10.6% | $4.1M+55.4% | $6.7M+254.6% | $7.4M+264.3% | $2.5M-56.8% | $2.6M | $1.9M | $2.0M-65.9% |
| Current Liabilities | $2.6M+2.7% | $3.9M+47.6% | $6.7M+256.2% | $7.4M+268.1% | $2.5M-55.7% | $2.6M | $1.9M | $2.0M-65.2% |
| Non-Current Liabilities | $198Kn/m | $205Kn/m | $0-100.0% | $0-100.0% | $0-100.0% | $0 | $9K | $21K-88.1% |
| Total Equity | -$1.2M-2123.8% | -$366K-127.3% | -$2.8M-190.8% | -$1.8M-143.9% | $57Kn/m | $1.3Mn/m | $3.1Mn/m | $4.2Mn/m |
| Retained Earnings | -$46.2Mn/m | -$39.0Mn/m | -$36.7Mn/m | -$34.7Mn/m | -$32.1Mn/m | -$29.8M | -$27.6M | -$26.0Mn/m |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
JUNS Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
JUNS Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 68.9% | 86.9% | 76.6% | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -41570.1% | -11313.4% | -10524.3% | N/A | N/A | N/A | N/A | N/A |
| Net Margin | -51815.2% | -9380.9% | -11054.9% | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | -3984.9% | -168.1% | -49.9% | -36.6% |
| Return on Assets | -445.1%-356.3pp | -61.2%-4.4pp | -52.2%-21.4pp | -46.3%-21.6pp | -88.8%+602.1pp | -56.8% | -30.8% | -24.6%+264.5pp |
| Current Ratio | 0.49-0.2x | 0.66-0.4x | 0.51-1.4x | 0.65-1.7x | 0.65+0.6x | 1.07 | 1.91 | 2.31+2.3x |
| Liabilities-to-Equity | N/A | N/A | N/A | N/A | 43.87 | 1.96 | 0.62 | 0.49 |
| Asset Turnover | 0.01 | 0.01 | 0.000.0x | N/A | N/A | N/A | 0.00 | N/A |
Not reported in any period shown, so not listed: Debt-to-Equity, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Note: Shareholder equity is negative (-$1.8M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.65), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Jupiter Neurosciences, Inc. JUNS | FY2025 | $22K | -$8.6M | N/A | $1.6M | — |
| Revelation Biosciences, Inc. REVB | FY2025 | N/A | -$8.9M | N/A | $2.0M | — |
| Clearmind Medicine Inc. CMND | FY2025 | N/A | -$3.9M | N/A | $1.3M | — |
| VivoSim Labs, Inc. VIVS | FY2026 | $131K | -$13.8M | N/A | $5.3M | — |
| Calidi Biotherapeutics, Inc. CLDI | FY2025 | N/A | -$19.9M | N/A | $1.6M | — |
| XORTX Therapeutics Inc. XRTX | FY2025 | N/A | -$2.7M | N/A | $1.9M | — |
Where Jupiter Neurosciences, Inc. Ranks
Frequently Asked Questions
Jupiter Neurosciences, Inc. (JUNS) reported $22K in total revenue for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
No, Jupiter Neurosciences, Inc. (JUNS) reported a net loss of $8.6M in fiscal year 2025.
Jupiter Neurosciences, Inc. (JUNS) had a gross margin of 80.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
Jupiter Neurosciences, Inc. (JUNS) recorded an outflow of $5.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Jupiter Neurosciences, Inc. (JUNS) had $5.6M in total assets as of fiscal year 2025, including both current and long-term assets.
Jupiter Neurosciences, Inc. (JUNS) invested $2.1M in research and development during fiscal year 2025.
Jupiter Neurosciences, Inc. (JUNS) had a current ratio of 0.65 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
Jupiter Neurosciences, Inc. (JUNS) had a return on assets of -155.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Jupiter Neurosciences, Inc. (JUNS) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $1.6M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Jupiter Neurosciences, Inc. (JUNS) trades at 74.7x sales, its market capitalization divided by $22K revenue, FY2025. The market capitalization is $1.6M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2025, Jupiter Neurosciences, Inc. (JUNS) held $3.8M in cash, cash equivalents and investments, and reported an operating cash outflow of $5.4M over that year. Dividing the one by the other, the reported balance equals about 8 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Jupiter Neurosciences, Inc. (JUNS) has negative shareholder equity of -$1.8M as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
Jupiter Neurosciences, Inc. (JUNS) has an Altman Z-Score of -14.42, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
Jupiter Neurosciences, Inc. (JUNS) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Jupiter Neurosciences, Inc. (JUNS) reported a net loss of $8.6M while operations used $5.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Jupiter Neurosciences, Inc. (JUNS) reported an operating loss of $8.9M against $66K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.